Dominik Bylica
Research Subjects
Dominik Bylica has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna Kaźmierska
Medical University of Silesia, Katowice, Poland
7 shared publications - Magdalena Bodera
Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland
7 shared publications - Radosław Szydłowski
Medical University of Silesia, Katowice, Poland
7 shared publications - Sonja Rozmus
Provincial Specialist Hospital of St. Barbara No. 5, Sosnowiec, Poland
6 shared publications - Hanna Porwolik
Medical University of Silesia, Katowice, Poland
4 shared publications - Anna Hamerla
Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
CANCER PAIN IN PALLIATIVE CARE: ASSESSMENT, MONITORING, AND THE ROLE OF NURSING
Cancer is one of the leading causes of death, following cardiovascular diseases. Despite significant advances in medicine, cancer incidence continues to rise, with the number of affected individuals having doubled over the past decades. Pain is the most common symptom experienced during the course of cancer. On average, approximately half of patients with cancer, at various stages of the disease, suffer from pain. According to the concept proposed by Cicely Saunders, founder of St Christopher’s Hospice in London, cancer pain is a multidimensional and overwhelming experience referred to as “total pain” which includes physical, psychological, social, and spiritual components. The aim of this study is to present the issue of pain in the course of cancer, to define appropriate nursing management strategies for the assessment and monitoring of this symptom, and to provide a descriptive analysis of current knowledge on pain and its treatment. This paper is based on a review of the relevant literature, including textbooks, scientific articles, and current legal regulations. It consists of three chapters addressing palliative care, the characteristics of cancer pain, and principles of nursing management in its assessment and control.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessCANCER PAIN IN PALLIATIVE CARE: ASSESSMENT, MONITORING, AND THE ROLE OF NURSING
Cancer is one of the leading causes of death, following cardiovascular diseases. Despite significant advances in medicine, cancer incidence continues to rise, with the number of affected individuals having doubled over the past decades. Pain is the most common symptom experienced during the course of cancer. On average, approximately half of patients with cancer, at various stages of the disease, suffer from pain. According to the concept proposed by Cicely Saunders, founder of St Christopher’s Hospice in London, cancer pain is a multidimensional and overwhelming experience referred to as “total pain” which includes physical, psychological, social, and spiritual components. The aim of this study is to present the issue of pain in the course of cancer, to define appropriate nursing management strategies for the assessment and monitoring of this symptom, and to provide a descriptive analysis of current knowledge on pain and its treatment. This paper is based on a review of the relevant literature, including textbooks, scientific articles, and current legal regulations. It consists of three chapters addressing palliative care, the characteristics of cancer pain, and principles of nursing management in its assessment and control.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
COMPLICATIONS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
Transcatheter aortic valve implantation (TAVI) has become an established and widely adopted treatment for patients with severe aortic stenosis across all surgical risk categories. Continuous technological progress, refinements in device design, and increasing operator experience have substantially improved procedural safety and expanded indications from inoperable and high-risk patients to those at intermediate and low surgical risk. Nevertheless, despite these advancements, TAVI remains associated with a broad spectrum of complications that may adversely affect both short- and long-term outcomes. This review provides a comprehensive overview of the most clinically significant complications following TAVI, including vascular, valvular, neurological, renal, bleeding, infectious, and conduction-related events. Particular attention is given to the underlying pathophysiological mechanisms, patient- and procedure-related risk factors, and contemporary prevention and management strategies. Although the incidence of major vascular complications has decreased with the introduction of lower-profile delivery systems, these events remain clinically relevant, particularly in elderly patients and those with complex vascular anatomy. Conduction disturbances frequently require permanent pacemaker implantation, while stroke and silent cerebral embolization continue to represent major neurological concerns. Acute kidney injury and major bleeding significantly contribute to morbidity and mortality, and prosthetic valve endocarditis, although rare, carries a particularly poor prognosis. A thorough understanding of the mechanisms and predictors of post-TAVI complications is essential for optimizing patient selection, procedural planning, and post-procedural management. Ongoing innovations in device technology and procedural techniques remain fundamental to further improving clinical outcomes and minimizing procedural risk.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessCOMPLICATIONS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
Transcatheter aortic valve implantation (TAVI) has become an established and widely adopted treatment for patients with severe aortic stenosis across all surgical risk categories. Continuous technological progress, refinements in device design, and increasing operator experience have substantially improved procedural safety and expanded indications from inoperable and high-risk patients to those at intermediate and low surgical risk. Nevertheless, despite these advancements, TAVI remains associated with a broad spectrum of complications that may adversely affect both short- and long-term outcomes. This review provides a comprehensive overview of the most clinically significant complications following TAVI, including vascular, valvular, neurological, renal, bleeding, infectious, and conduction-related events. Particular attention is given to the underlying pathophysiological mechanisms, patient- and procedure-related risk factors, and contemporary prevention and management strategies. Although the incidence of major vascular complications has decreased with the introduction of lower-profile delivery systems, these events remain clinically relevant, particularly in elderly patients and those with complex vascular anatomy. Conduction disturbances frequently require permanent pacemaker implantation, while stroke and silent cerebral embolization continue to represent major neurological concerns. Acute kidney injury and major bleeding significantly contribute to morbidity and mortality, and prosthetic valve endocarditis, although rare, carries a particularly poor prognosis. A thorough understanding of the mechanisms and predictors of post-TAVI complications is essential for optimizing patient selection, procedural planning, and post-procedural management. Ongoing innovations in device technology and procedural techniques remain fundamental to further improving clinical outcomes and minimizing procedural risk.
- Open Access
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
VERICIGUAT: MODERN THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
Vericiguat is the first oral soluble guanylate cyclase (sGC) stimulator developed to reduce the risk of cardiovascular death and heart failure–related hospitalizations in patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF). sGC dysfunction, resulting in impaired synthesis of cyclic guanosine monophosphate (cGMP), may play a keyrole in the pathophysiology of heart failure by affecting myocardial function, vascular tone, and peripheral tissue perfusion. Vericiguat exerts its therapeutic effect by enhancing intracellular cGMP levels, leading to improved cardiac function and vasodilation. Consequently, the drug represents a promising treatment option for patients with HFrEF, particularly those with recent decompensation, requiring intravenous diuretic therapy, or at high risk for rehospitalization due to disease exacerbation. Clinical efficacy of vericiguat was demonstrated in the VICTORIA trial, which enrolled 6,857 patients with HFrEF following recent decompensation. After a median follow-up of 10.8 months, treatment with vericiguat significantly reduced the risk of the composite endpoint of cardiovascular death or heart failure related hospitalization compared with placebo. Patients with more advanced disease also exhibited reductions in NT-proBNP levels, suggesting a potential biomarker of therapeutic response. Vericiguat is generally well tolerated. The most commonly reported adverse events are hypotension and syncope. The drug can be safely administered to patients with mild to moderate renal or hepatic impairment, although data in severe organ dysfunction are lacking. Dose adjustments are not required based on age or body weight. The introduction of vericiguat into the management of HFrEF represents a meaningful advancement in therapy. While the drug does not significantly extend overall survival, its use is associated with a substantial reduction in the risk of recurrent hospitalizations, which may have important clinical and prognostic implications in this patient population.
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessVERICIGUAT: MODERN THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
Vericiguat is the first oral soluble guanylate cyclase (sGC) stimulator developed to reduce the risk of cardiovascular death and heart failure–related hospitalizations in patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF). sGC dysfunction, resulting in impaired synthesis of cyclic guanosine monophosphate (cGMP), may play a keyrole in the pathophysiology of heart failure by affecting myocardial function, vascular tone, and peripheral tissue perfusion. Vericiguat exerts its therapeutic effect by enhancing intracellular cGMP levels, leading to improved cardiac function and vasodilation. Consequently, the drug represents a promising treatment option for patients with HFrEF, particularly those with recent decompensation, requiring intravenous diuretic therapy, or at high risk for rehospitalization due to disease exacerbation. Clinical efficacy of vericiguat was demonstrated in the VICTORIA trial, which enrolled 6,857 patients with HFrEF following recent decompensation. After a median follow-up of 10.8 months, treatment with vericiguat significantly reduced the risk of the composite endpoint of cardiovascular death or heart failure related hospitalization compared with placebo. Patients with more advanced disease also exhibited reductions in NT-proBNP levels, suggesting a potential biomarker of therapeutic response. Vericiguat is generally well tolerated. The most commonly reported adverse events are hypotension and syncope. The drug can be safely administered to patients with mild to moderate renal or hepatic impairment, although data in severe organ dysfunction are lacking. Dose adjustments are not required based on age or body weight. The introduction of vericiguat into the management of HFrEF represents a meaningful advancement in therapy. While the drug does not significantly extend overall survival, its use is associated with a substantial reduction in the risk of recurrent hospitalizations, which may have important clinical and prognostic implications in this patient population.
- Open Access
- 2 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
NO-REFLOW PHENOMENON – MECHANISM, PREVENTION AND TREATMENT STRATEGIES
No-reflow phenomenon is a major clinical problem in the treatment of acute myocardial infarction, which happens despite effective recanalization of the epicardial coronary arteries. It is also marked by compromised microvascular blood circulation and it is linked to poor clinical outcome, such as bigger infarct size, left ventricular remodeling and higher mortality rates. The lack of no-reflow pathophysiology is multifactorial in nature and consists of distal microthromboembolization, reperfusion injury, endothelial dysfunction, microvascular spasm, and excessive inflammatory response. The no-reflow diagnosis continues to be difficult. Angiographic techniques such as Thrombolysis In Myocardial Infarction (TIMI) flow grade, which are used widely, are not very effective in evaluating microvascular perfusion. Higher resolution imaging including cardiac magnetic resonance imaging, myocardial contrast echocardiography, among others, offer a more accurate analysis; nevertheless, their application in clinical practice is limited due to their infrequent availability and high cost. No-reflow phenomenon is also a complicated combating mechanism. The existing approaches to therapy are mainly directed at alleviating the burden of thrombus, limiting the area of infarction, and alleviating reperfusion damages. However, the efficacy of these methods is dynamic and inadequately frequently, and no single therapy aimed at the coronary microvascular dysfunction development is determined. This means that more investigations about the mechanism behind no-reflow, the creation of more sensitive diagnostic techniques, and specific treatment of no-reflow have to be taken to enhance microvascular reperfusion and patient outcome.
- 2 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessNO-REFLOW PHENOMENON – MECHANISM, PREVENTION AND TREATMENT STRATEGIES
No-reflow phenomenon is a major clinical problem in the treatment of acute myocardial infarction, which happens despite effective recanalization of the epicardial coronary arteries. It is also marked by compromised microvascular blood circulation and it is linked to poor clinical outcome, such as bigger infarct size, left ventricular remodeling and higher mortality rates. The lack of no-reflow pathophysiology is multifactorial in nature and consists of distal microthromboembolization, reperfusion injury, endothelial dysfunction, microvascular spasm, and excessive inflammatory response. The no-reflow diagnosis continues to be difficult. Angiographic techniques such as Thrombolysis In Myocardial Infarction (TIMI) flow grade, which are used widely, are not very effective in evaluating microvascular perfusion. Higher resolution imaging including cardiac magnetic resonance imaging, myocardial contrast echocardiography, among others, offer a more accurate analysis; nevertheless, their application in clinical practice is limited due to their infrequent availability and high cost. No-reflow phenomenon is also a complicated combating mechanism. The existing approaches to therapy are mainly directed at alleviating the burden of thrombus, limiting the area of infarction, and alleviating reperfusion damages. However, the efficacy of these methods is dynamic and inadequately frequently, and no single therapy aimed at the coronary microvascular dysfunction development is determined. This means that more investigations about the mechanism behind no-reflow, the creation of more sensitive diagnostic techniques, and specific treatment of no-reflow have to be taken to enhance microvascular reperfusion and patient outcome.
- Open Access
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
USE OF VERCIGUAT IN THE TREATMENT OF HEART FAILURE
Heart failure remains a major challenge in contemporary cardiology, characterized by high morbidity, frequent hospitalizations, and an unfavorable prognosis despite substantial advances in guideline-directed therapy. Although modern multidrug treatment has improved clinical outcomes, a considerable proportion of patients continue to experience disease progression and recurrent exacerbations, particularly in high-risk populations. Vericiguat is a novel oral agent used in the treatment of heart failure and represents an adjunct to standard therapy in selected patients. To date, clinical studies have evaluated the efficacy and safety of vericiguat in patients with both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Available evidence suggests that the clinical effects of vericiguat vary depending on the heart failure phenotype and the clinical context, including disease stability and the risk of further deterioration. This paper provides a comprehensive review of current data on the use of vericiguat across different heart failure phenotypes, with particular emphasis on clinical trial outcomes, therapeutic efficacy, and safety profile. The limitations of existing evidence are discussed, along with the potential role of vericiguat within contemporary treatment strategies. Overall, current findings indicate that vericiguat should not be regarded as a universal therapy for all patients with heart failure, but rather as a complementary treatment option for carefully selected individuals, in whom additional therapeutic strategies may be required.
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessUSE OF VERCIGUAT IN THE TREATMENT OF HEART FAILURE
Heart failure remains a major challenge in contemporary cardiology, characterized by high morbidity, frequent hospitalizations, and an unfavorable prognosis despite substantial advances in guideline-directed therapy. Although modern multidrug treatment has improved clinical outcomes, a considerable proportion of patients continue to experience disease progression and recurrent exacerbations, particularly in high-risk populations. Vericiguat is a novel oral agent used in the treatment of heart failure and represents an adjunct to standard therapy in selected patients. To date, clinical studies have evaluated the efficacy and safety of vericiguat in patients with both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Available evidence suggests that the clinical effects of vericiguat vary depending on the heart failure phenotype and the clinical context, including disease stability and the risk of further deterioration. This paper provides a comprehensive review of current data on the use of vericiguat across different heart failure phenotypes, with particular emphasis on clinical trial outcomes, therapeutic efficacy, and safety profile. The limitations of existing evidence are discussed, along with the potential role of vericiguat within contemporary treatment strategies. Overall, current findings indicate that vericiguat should not be regarded as a universal therapy for all patients with heart failure, but rather as a complementary treatment option for carefully selected individuals, in whom additional therapeutic strategies may be required.
- Open Access
- 23 March 2026
- Published by National Institute of Public Health NIH (National Research Institute) in Przeglad Epidemiologiczny
- Vol. 80 (1) , 116-132
Air pollution and cardiovascular disease: A review of current scientific data
Introduction and Aim Air pollution is a major public health concern, adversely affecting both the respiratory and cardiovascular systems. The main pollutants include particulate matter (PM2.5, PM10), nitrogen oxides (NO2), tropospheric ozone (O3), carbon monoxide (CO), sulfur dioxide (SO2), and other toxic compounds. Numerous studies confirm an association between exposure to these pollutants and increased incidence of cardiovascular diseases, including ischemic heart disease, stroke, arrhythmias, and heart failure. This paper aims to summarise current knowledge on the effects of air pollution on the cardiovascular system and to discuss underlying pathophysiological mechanisms. State of Knowledge Air pollution is one of the leading environmental risk factors for premature mortality worldwide. The most harmful components include fine particulate matter (PM2.5), nitrogen oxides (NO2), ozone (O3), carbon monoxide (CO), and sulfur dioxide (SO₂). In 2021, the World Health Organisation (WHO) revised its air quality guidelines, lowering the recommended annual PM2.5 limit to 5 µg/m3. Pollutants induce oxidative stress, inflammation, endothelial dysfunction, and autonomic imbalance, contributing to cardiovascular disease development and progression. Short-term exposure increases the risk of acute events such as myocardial infarction and arrhythmias, while long-term exposure promotes atherosclerosis and chronic heart failure. The elderly, children, and individuals with chronic diseases are particularly vulnerable. This issue remains a major public health challenge globally. Summary Air pollution is a key risk factor for cardiovascular disease. Reducing exposure through continuous air quality monitoring and effective preventive measures is essential for protecting public health.
- 23 March 2026
- Published by National Institute of Public Health NIH (National Research Institute) in Przeglad Epidemiologiczny
- Vol. 80 (1) , 116-132
Open AccessAir pollution and cardiovascular disease: A review of current scientific data
Introduction and Aim Air pollution is a major public health concern, adversely affecting both the respiratory and cardiovascular systems. The main pollutants include particulate matter (PM2.5, PM10), nitrogen oxides (NO2), tropospheric ozone (O3), carbon monoxide (CO), sulfur dioxide (SO2), and other toxic compounds. Numerous studies confirm an association between exposure to these pollutants and increased incidence of cardiovascular diseases, including ischemic heart disease, stroke, arrhythmias, and heart failure. This paper aims to summarise current knowledge on the effects of air pollution on the cardiovascular system and to discuss underlying pathophysiological mechanisms. State of Knowledge Air pollution is one of the leading environmental risk factors for premature mortality worldwide. The most harmful components include fine particulate matter (PM2.5), nitrogen oxides (NO2), ozone (O3), carbon monoxide (CO), and sulfur dioxide (SO₂). In 2021, the World Health Organisation (WHO) revised its air quality guidelines, lowering the recommended annual PM2.5 limit to 5 µg/m3. Pollutants induce oxidative stress, inflammation, endothelial dysfunction, and autonomic imbalance, contributing to cardiovascular disease development and progression. Short-term exposure increases the risk of acute events such as myocardial infarction and arrhythmias, while long-term exposure promotes atherosclerosis and chronic heart failure. The elderly, children, and individuals with chronic diseases are particularly vulnerable. This issue remains a major public health challenge globally. Summary Air pollution is a key risk factor for cardiovascular disease. Reducing exposure through continuous air quality monitoring and effective preventive measures is essential for protecting public health.
- Open Access
- 5 March 2026
- Published by Institute of Rural Health in Environmental Medicine
Impact of shift work on human health
Introduction and objective: Shift work, including night work and rotating shifts, is a common form of work organisation in modern societies. It leads to chronic disruption of the circadian rhythm, sleep and neurohormonal regulation, which may contribute to the development of numerous health...
- 5 March 2026
- Published by Institute of Rural Health in Environmental Medicine
Open AccessImpact of shift work on human health
Introduction and objective: Shift work, including night work and rotating shifts, is a common form of work organisation in modern societies. It leads to chronic disruption of the circadian rhythm, sleep and neurohormonal regulation, which may contribute to the development of numerous health...